RNA as a drug target.
Historically, the pharmaceutical industry has focused on proteins, rather than nucleic acids, as drug targets. But recent advances in the fields of RNA synthesis, structure determination and therapeutic target identification make the systematic exploitation of RNA as a drug target a realistic goal.
Pearson
N D
ND
Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex, CM19 5AW, UK. neil_pearson-1@sbphrd.com
Prescott
C D
CD
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents; D000998:Antiviral Agents; D001665:Binding Sites; D003432:Cross-Linking Reagents / Q000378:metabolism; D018360:Crystallography, X-Ray; D015195:Drug Design; D008024:Ligands; D008958:Models, Molecular; D009690:Nucleic Acid Conformation; D010303:Paromomycin / Q000494:pharmacology; D012313:RNA / Q000737:chemistry / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D012322:RNA Precursors / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D012331:RNA, Fungal / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000998:Antiviral Agents; D003432:Cross-Linking Reagents; D008024:Ligands; D012322:RNA Precursors; D012331:RNA, Fungal; D016601:RNA-Binding Proteins; D010303:Paromomycin; D012313:RNA